Navigation Links
Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
Date:9/13/2007

Adlea May Provide Pain Relief Without Opiate-Like Side Effects For Several

Months Following a Single Administration

SOUTH SAN FRANCISCO, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it has initiated a new Phase 2 study of Adlea(TM) (formerly 4975) for the relief of post-operative pain in patients undergoing total knee replacement surgery, also called total knee arthroplasty (TKA). Adlea is a long-acting, non-opiate analgesic drug designed to provide pain relief for weeks to months after a single local administration during the surgical procedure.

"Given the positive preliminary results from our studies of Adlea in a number of clinical settings, we believe that Adlea offers a unique profile of powerful pain reduction without the side effects common to many medicines for moderate to severe pain," said John P. McLaughlin, chief executive officer of Anesiva. "In total knee replacement surgery, up to 80 percent of these patients will experience moderate to severe pain following this surgery with current pain medications as well as the side effects associated with those pain medicines, such as vomiting, nausea and sedation. We believe Adlea may offer significant and continuous lasting relief from the moderate to severe pain that commonly follows this procedure. We look forward to obtaining additional results in this indication."

Previously, the company successfully studied a 5mg dose of Adlea in patients who had completed total knee replacement. The new trial will evaluate a higher dose of Adlea-15mg-relative to 5mg and placebo in a double-blind, multi-center study of approximately 80 TKA patients. This 15mg dose equates to a higher drug con
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... Women,s sexual health company, Ti...Viveve as it prepares for a 2010 launch of its Viv..., "Viveve is a name that we believe captures the e...th," said Kerry Pope, Viveve,s president and chief... helping women restore their sense of fulfillment ...
(Date:11/9/2009)... 9 LifeNet Health, a leading allog...Vertigraft Cervical Bio-Implant (VG2C) with Preser...w, proprietary glycerol-based preservation solutio...in a fully hydrated state at ambient temperature. ...io-implants, doing away with lengthy thawing and r...
(Date:11/9/2009)...Newswire-FirstCall/ -- RBC Life Sciences, Inc. ...tary nutritional supplements and wound care/pain m...100 workplaces in the Dallas-Fort Worth area. ,...100 Places to Work 2009 competition surveyed more ... and large firms throughout the DFW metropolitan a...
Breaking Medicine Technology:Women's Sexual Health Company Changes Name in Preparation for Market Entry 2LifeNet Health Announces First Bio-Implant with New Preservation Technology 2RBC Life Sciences Ranked as One of the Top 100 Workplaces in the Dallas-Fort Worth Area 2Edmond Scientific Company Rallies as Certifications 26 Assessments 28C 26A 29 Provider for HIEs Pursuing ARRA ONC Grants 55743 1Edmond Scientific Company Rallies as Certifications 26 Assessments 28C 26A 29 Provider for HIEs Pursuing ARRA ONC Grants 55743 2SCOLR Pharma Inc Appoints Stephen J Turner as CEO 55740 1SCOLR Pharma Inc Appoints Stephen J Turner as CEO 55740 2SCOLR Pharma Inc Appoints Stephen J Turner as CEO 55740 3New Study of House Health Reform Bill 3A New Mexico Faces Over 24130 Million in Medicare Funded Nursing Home Cuts Over Ten Years 55737 1New Study of House Health Reform Bill 3A New Mexico Faces Over 24130 Million in Medicare Funded Nursing Home Cuts Over Ten Years 55737 2
... Orexigen(R) Therapeutics, Inc.,(Nasdaq: OREX )... resources,focus its efforts on its late-stage obe... The key aspects of these changes are as follo...hase 2 trials for OREX-003,(zonisamide and olanzap...in),and OREX-004 (fluoxetine and naltrexone to red...
...LR8 Agonist to Advance to Clinical Trials , , ... a biopharmaceutical company focused on the develo...s for the treatment of cancer, respiratory and aut...iated a Phase I clinical trial of VTX-2337, a sele...he multi-center clinical trial is being conducted ...
Other Medicine Technology:Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 2Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 3VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology 2
(Date:11/9/2009)...abbits implanted with new cells regained sexual fu...9 (HealthDay News) -- Researchers were able to res...es by growing new penile tissue in the lab and imp...an application is a ways off, researchers say the ...ectile dysfunction in men. , "We were able to s...
(Date:11/9/2009)... Course, to be Offered in ...sic Toolkit , Cambridge, ... of Physicians for Human Rights (PHR) first inspec...ghanistan , he realized he would need a team of ex...cumenting the site properly was a key first step i...
(Date:11/9/2009)..., March of Dimes Names 2010 National Ambassad...USNewswire/ -- Joshua Hoffman of Weston, Fla., was...ans that doctors could not say whether he would su...ar. Today, the 6-year-old was named March of Dimes...lanie Hoffman, recalls, "My first minutes of mothe...
(Date:11/9/2009)...tudy didn,t answer question of why this is so, how...s) -- After a lumpectomy, women with very dense br...he affected breast, a new study shows. , Breast... risk of developing breast cancer, and experts hav...sociated with an increased risk of cancer recurren...
(Date:11/9/2009)..., PITTSFIELD, Maine, Nov. 9 At ...nts in Maine are increasingly concerned about find...ompetitive Medicare option for 2010. ,, The Tod... (PPO) Medicare Advantage plan provides a cost-eff...edicare or a Medicare Supplement plan. People wit...
Breaking Medicine News(10 mins):Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3Health News:Maine Residents With Medicare Searching for Affordable and Innovative Insurance Have Competitive Medicare Advantage Option 2
... Terri Milen of TEM Counseling LLC lau...terrimilen.com [Online Counseling via video/phone...] to clients in the comfort of their own home or o...which requires clients to make room for another ap...
...no sample traced back to Mexican farm, FDA announc...- Almost a week after uncovering the first big cl...lth officials announced Friday that tainted jalape...s grown in the United States, but warned consumers...
...o discuss second quarter financial results -, LAV... Inc. (TSX: DDS;,NASDAQ: DDSS) today announced tha... 8 at 8:30 a.m. (ET) to discuss its second quarter...o access the conference call by telephone, dial 41...
... cleaning products reduces lung function, increase...uly 25 (HealthDay News) -- A clean, fresh-smelling...ng on what type of cleaning and air freshening pro...called 1,4 dicholorobenzene (1,4 DCB), can reduce ...
...5 BeaconEquity.com announces the,availability of ...ors can view all of the daily trading notes for fr...y,s Trade Alerts include: DUSA Pharmaceuticals Inc...daq: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX )., J...
...Marketing Exclusivity Begins -, CORONA, Calif., J..., a leading specialty pharmaceutical,company, anno...ercial,shipment of its Omeprazole Delayed-Release ...ting exclusivity for being the,first to file an AN...
Other Medicine News:Health News:Online Counseling and Life Coaching Practice Launches New Website 2Health News:Mexican Peppers ID'd as Salmonella Culprits 2Health News:Mexican Peppers ID'd as Salmonella Culprits 3Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2
Liquichek Reticulocyte Control
Liquichek ToRCH Plus IgM Controls
Liquichek Seroconversion Panels
Amplichek CT/GC Controls
Medicine Products: